Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential

Abstract

Despite the fact that non-alcoholic fatty liver disease (NAFLD) and its severe clinical forms [non-alcoholic steatohepatitis (NASH) and NASH-cirrhosis] are highly prevalent in the general population, there are no licensed drugs for NAFLD, and lifestyle intervention remains the only treatment accepted by international guidelines. This is despite massive investments in research by pharmaceutical companies. In the presence of type 2 diabetes, novel anti-diabetic drugs offer an opportunity to reduce the burden of NAFLD, by adequate control of glucose and lipid metabolism, also reducing the risk of NASH progression, advanced fibrosis, and finally hepatocellular carcinoma. We extensively reviewed the literature, based either on registration studies, ad hoc randomized studies or real-world data, to define the effectiveness of anti-diabetic drugs in the treatment of NAFLD and prevention of hepatocellular carcinoma (HCC). Metformin provides the best evidence for decreased risk of HCC, pioglitazone was associated with decreased progression to fibrosis, glucagon-like peptide-1 receptor agonists offer a possible opportunity to reduce NAFLD progression coupled with a definite protection for cardiovascular outcomes, and sodium-glucose cotransporter-2 inhibitors are likely to reduce lipid burden, simultaneously reducing the risk of progressive renal and heart failure. For the latter two drug classes, the effects on NAFLD might largely explained by decreased body weight, in keeping with the beneficial effects of intensive lifestyle intervention.

Keywords

Metformin / pioglitazone / incretins / DPP-4 inhibitors / GLP-1 receptor agonists / SGLT-2 inhibitors / insulin / cirrhosis

References

[1] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes..Hepatology2016;64:73-84

[2] Petta S,Pipitone RM.Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population..Liver Int2018;38:2060-8

[3] Taylor RS,Bayliss S.Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis..Gastroenterology2020;158:1611-25.e12

[4] Loria P,Nascimbeni F.Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology..Atherosclerosis2014;232:99-109

[5] Marchesini G.Nonalcoholic fatty liver disease and the metabolic syndrome..Minerva Cardioangiol2006;54:229-39

[6] Ekstedt M,Mathiesen UL,Holmqvist M.Long-term follow-up of patients with NAFLD and elevated liver enzymes..Hepatology2006;44:865-73

[7] Italian Association for the Study of the Liver (AISF)AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions..Dig Liver Dis2017;49:471-83

[8] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease..J Hepatol2016;64:1388-402

[9] Sanyal AJ.Past, present and future perspectives in nonalcoholic fatty liver disease..Nat Rev Gastroenterol Hepatol2019;16:377-86

[10] Sanyal AJ,Kleiner DE.Endpoints and clinical trial design for nonalcoholic steatohepatitis..Hepatology2011;54:344-53 PMCID:PMC4014460

[11] Rinella ME.STELLAR 3 and STELLAR 4: lessons from the fall of Icarus..J Hepatol2020;73:9-11 PMCID:PMC7191297

[12] Younossi ZM,Loomba R.Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial..Lancet2019;394:2184-96

[13] Intercept release. Complete Response Letter (CRL) from the FDA regarding our new drug application for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH. Available from: https://ir.interceptpharma.com/news-releases/news-release-details/intercept-receives-complete-response-letter-fda-obeticholic-acid;2020. [Last accessed on 22 Oct 2020]

[14] Portillo-Sanchez P,Maximos M.High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels..J Clin Endocrinol Metab2015;100:2231-8 PMCID:PMC6287506

[15] Hazlehurst JM,Marjot T,Tomlinson JW.Non-alcoholic fatty liver disease and diabetes..Metabolism2016;65:1096-108 PMCID:PMC4943559

[16] Hossain N,Stepanova M.Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease..Clin Gastroenterol Hepatol2009;7:1224-929.e1-2

[17] Jarvis H,Barker R.Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies..PLoS Med2020;17:e1003100 PMCID:PMC7192386

[18] Ballestri S,Targher G.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis..J Gastroenterol Hepatol2016;31:936-44

[19] Marchesini G,Forlani G.Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome..Hepatology2003;37:917-23

[20] Marchesini G,Bianchi G.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome..Diabetes2001;50:1844-50

[21] Taylor R.Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause..Diabetologia2008;51:1781-9

[22] American Diabetes Association9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020..Diabetes Care2020;43:S98-110

[23] Kristensen SL,Jhund PS.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials..Lancet Diab Endocrinol2019;7:776-85

[24] Zelniker TA,Raz I.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials..Lancet2019;393:31-9

[25] U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research. Guidance for Industry. Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available from: http://wwwfdagov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627pdf. [Last accessed on 22 Oct 2020]

[26] Nissen SE.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes..N Engl J Med2007;356:2457-71

[27] Lincoff AM,Nicholls SJ.Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials..JAMA2007;298:1180-8

[28] Musso G,Paschetta E.Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges..Hepatology2017;65:1058-61

[29] Donadon V,Mas MD,Zanette G.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease..Liver Int2010;30:750-8

[30] Zhang ZJ,Shi R,Jiang Q.Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis..J Clin Endocrinol Metab2012;97:2347-53

[31] Singh S,Singh AG,Sanchez W.Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis..Am J Gastroenterol2013;108:881-91quiz 892

[32] Yu H,Gao P.The potential effect of metformin on cancer: an umbrella review..Front Endocrinol (Lausanne)2019;10:617 PMCID:PMC6760464

[33] Zhang X,Mettler TA.Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes..Hepatology2014;60:2008-16 PMCID:PMC4218882

[34] Hauner H.The mode of action of thiazolidinediones..Diabetes Metab Res Rev2002;18:S10-5

[35] Hauner H.The mode of action of thiazolidinediones..Diabetes Metab Res Rev2002;18:S10-5

[36] Belfort R,Brown K,Finch J.A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis..N Engl J Med2006;355:2297-307

[37] Belfort R,Brown K.A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis..N Engl J Med2006;355:2297-307

[38] Chalasani NP,Kowdley KV.Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design..Contemp Clin Trials2009;30:88-96 PMCID:PMC2929909

[39] Promrat K,Uwaifo GI.A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis..Hepatology2004;39:188-96

[40] Sanyal AJ,Kowdley KV.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis..N Engl J Med2010;362:1675-85 PMCID:PMC2928471

[41] Musso G,Paschetta E.Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis..JAMA Intern Med2017;177:633-40 PMCID:PMC5470366

[42] Dormandy JA,Eckland DJ.Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial..Lancet2005;366:1279-89

[43] Kernan WN,Furie KL.Pioglitazone after ischemic stroke or transient ischemic attack..N Engl J Med2016;374:1321-31 PMCID:PMC4887756

[44] Chang CH,Wu LC,Chuang LM.Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus..Hepatology2012;55:1462-72

[45] Bril F,Kalavalapalli S,Cusi K.223-OR: Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis (NASH) is associated with disease recurrence..Diabetes2019;68:223-OR

[46] Motola D,Biagi C.Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database..Drug Saf2012;35:315-23

[47] Drucker DJ.The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes..Lancet2006;368:1696-705

[48] Carbone LJ,Yeomans ND.Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis..J Gastroenterol Hepatol2016;31:23-31

[49] Yilmaz Y,Deyneli O,Kalayci C.Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis..Acta Gastroenterol Belg2012;75:240-4

[50] Kanazawa I,Sugimoto T.DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus..Med Sci Monit2014;20:1662-7 PMCID:PMC4173801

[51] Alam S,Mustafa G,Ahmad N.Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial..Hepat Med2018;10:23-31 PMCID:PMC5931194

[52] Cui J,Nguyen P.Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial..J Hepatol2016;65:369-76 PMCID:PMC5081213

[53] Smits MM,Muskiet MH.Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial..Diabetologia2016;59:2588-93 PMCID:PMC6518065

[54] Brown E,Wilding JP.Newer GLP-1 receptor agonists and obesity-diabetes..Peptides2018;100:61-7

[55] Armstrong MJ,Rowe IA.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program..Aliment Pharmacol Ther2013;37:234-42

[56] Eguchi Y,Hyogo H.Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)..Hepatol Res2015;45:269-78

[57] Armstrong MJ,Aithal GP.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study..The Lancet2016;387:679-90

[58] Cusi K,García-Pérez LE.Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme..Diabet Med2018;35:1434-9

[59] Buse JB,Nielsen LL.Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials..Clin Ther2007;29:139-53

[60] Kenny PR,Torres DM,Chalasani N.Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series..Am J Gastroenterol2010;105:2707-9

[61] Dutour A,Ancel P.Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy..Diabetes Obes Metab2016;18:882-91

[62] Cuthbertson DJ,Gardner CJ.Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists..PLoS One2012;7:e50117 PMCID:PMC3516516

[63] Fan H,Xu Y.Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease..Arq Bras Endocrinol Metabol2013;57:702-8

[64] Sathyanarayana P,Muthupillai R,Samson SL.Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes..Obesity (Silver Spring)2011;19:2310-5

[65] NOVO Nordisk. Semaglutide in NASH phase 2 trial successfully completed. Financial report for the period 1 January 2020 to 31 March 2020. Available from: https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2020/Financial%20report%20for%20Q1%202020.pdf;2020. [Last accessed on 22 Oct 2020]

[66] NOVO Nordisk. Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial. In: editor^editors, editor. GlobeNewswire. Available from: https://ml-eu.globenewswire.com/Resource/Download/4951d1a2-3bd1-47ea-840a-a1234109c018;2020. [Last accessed on 22 Oct 2020]

[67] Zinman B,Buse JB.Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial..Diabetes Care2019;42:2262-71 PMCID:PMC7364672

[68] Vukotic R,Brodosi L.The effect of liraglutide on β-blockade for preventing variceal bleeding: a case series..Ann Intern Med2020;173:404-5

[69] Drucker DJ.The cardiovascular biology of glucagon-like peptide-1..Cell Metab2016;24:15-30

[70] Simes BC.Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide..Diabetes Metab Syndr Obes2019;12:2125-36 PMCID:PMC6799898

[71] Wu JHY,Blomster J.Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis..2016;4:411-9

[72] Kluger AY,Lee AY.Class effects of SGLT2 inhibitors on cardiorenal outcomes..Cardiovasc Diabetol2019;18:99 PMCID:PMC6683461

[73] Cai X,Gao X.The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis..Obesity (Silver Spring)2018;26:70-80

[74] Raschi E,Forcesi E.Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems..Nutr Metab Cardiovasc Dis2017;27:1098-107

[75] Eriksson JW,Jansson PA.Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study..Diabetologia2018;61:1923-34 PMCID:PMC6096619

[76] Kuchay MS,Mishra SK.Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)..Diabetes Care2018;41:1801-8

[77] Inoue M,Taguchi T.Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease..J Diabetes Investig2019;10:1004-11 PMCID:PMC6626966

[78] Kurinami N,Yoshida A.Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus..Diabetes Res Clin Pract2018;142:254-63

[79] Shimizu M,Kato K.Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease..Diabetes Obes Metab2019;21:285-92

[80] Sattar N,Hantel S,Zinman B.Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial..Diabetologia2018;61:2155-63 PMCID:PMC6133166

[81] Choi DH,Mok JO,Kang SK.Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease..Endocrinol Metab (Seoul)2018;33:387-94 PMCID:PMC6145967

[82] Bajaj HS,Bhullar L,Kalra S.SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes..Diabetes Metab2018;44:493-9

[83] Akuta N,Kawamura Y.Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies..Hepatol Commun2017;1:46-52 PMCID:PMC5747031

[84] Wang H,Chen X,Li J.Effects of sodium-glucose cotransporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus: a bayesian network meta-analysis..Clin Ther2019;41:322-34.e11

[85] Hung MH,Chen LJ.Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation..Cell Death Dis2019;10:420 PMCID:PMC6541593

[86] Del Prato S.Heterogeneity of diabetes: heralding the era of precision medicine..Lancet Diab Endocrinol2019;7:659-61

[87] Tricco AC,Soobiah C.Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis..Syst Rev2013;2:47 PMCID:PMC3702520

[88] Liu ST,Zhang LH,Zhao WX.Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus: a protocol for systematic review and network meta-analysis..Medicine (Baltimore)2020;99:e21568 PMCID:PMC7593046

[89] MacIsaac RJ.Dulaglutide and insulin: how can the AWARD studies help guide clinical practice?.Diabetes Ther2020;11:1627-38 PMCID:PMC7376989

[90] Abdul-Ghani M,Megahed A,Al-Ozairi E.Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study..Diabetes Obes Metab2020;

[91] Vilsbøll T,Johnsson E,Jabbour S.Dapagliflozin plus saxagliptin add-on therapy compared with insulin in patients with type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: a randomized clinical trial..Diabetes Care2019;42:1464-72

[92] Zaccardi F,Dales J.Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials..Diabetes Obes Metab2018;20:985-97

[93] Cherney DZI,Barbour SJ.Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial..Lancet Diab Endocrinol2020;8:582-93

[94] Papazafiropoulou AK,Antonopoulos S.Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes..Curr Pharm Des2020;

[95] Vincent RK,Evans M.A look to the future in non-alcoholic fatty liver disease: are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?.Diabetes Obes Metab2020;

[96] Brodosi L,Petroni ML.NASH: a glance at the landscape of pharmacological treatment..Ann Hepatol2016;15:673-81